The Effect of Thyroid Eye Disease on Corneal Biomechanical Properties

Objective & Hypothesis:Objectives: The aim of this study was to identify corneal biomechanical parameters measured by ORA in patients with TED compared to the healthy group.

📊

Key Findings & Data:Methods: We included 22 TED patients, diagnosed with TED for more than five years, and 43 healthy participants.

💡

Conclusion & Impact:CRF value might be a useful parameter in follow-up of TED patients in clinical practice.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to identify corneal biomechanical parameters measured by ORA in patients with TED compared to the healthy group. The NOSPECS classification of patients is used to assess the relation between biomechanical changes and disease severity. Methods: We included 22 TED patients, diagnosed with TED for more than five years, and 43 healthy participants. The NOSPECS classification was assessed as mild (grade 1-3) and severe (grade 4-6) disease. For each group, corneal hysteresis (CH), corneal resistance factor (CRF), central corneal thickness (CCT), Goldmann-correlated intraocular pressure (IOPg) and corneal compensated intraocular pressure (IOPcc) parameters were measured by ORA. Results: The mean age was 38.8±11.6 years for the TED patients and 42.9±15.58 years for the control group. For TED patients and healthy volunteers, the mean levels of CRF, CH, and CCT were measured as follows: 10.43±2.04 vs 10.28±1.91mmHg, p=0.67; 10.18±1.81 vs 10.21±1.68 mmHg, p=0.90; 550.31±35.73 vs 545.23±37.91 μm, p=0.47, respectively. These values were not significant between groups, but they were significantly higher in females compared to males in TED patients [CRF;10.68 (IQR: 9.49-12.14) vs 8.96 (IQR: 8.04-9.92) mmHg, p=0.002, CH; 10.43 (IQR: 9.48-11.25) vs 8.58 (IQR: 7.90-9.95) mmHg, p=0.003 and CCT; 554.25 (IQR: 536.05-579.52) vs 527.40 (IQR: 492.25-545.90) μm, p=0.014]. CRF values were negatively correlated with NOSPECS score (r=-0.317, p=0.036) and significantly higher CRF was observed in mild patients compared to severe disease (11.43 (IQR: 10.14-12.87) vs 9.46 (IQR: 8.75-10.28) mmHg, p=0.008). Conclusion: We found a significant gender effect on corneal biomechanical parameters of TED patients. CRF, CH and CCT values were significantly higher in females compared to males with TED. The clinical severity score of TED showed negative correlation with CRF. CRF value might be a useful parameter in follow-up of TED patients in clinical practice.

🔖

Cite This Article

CÖMERT, M. C., YILMAZ, S., TAŞ, A. Y., ŞAHİN, A. (2022). The Effect of Thyroid Eye Disease on Corneal Biomechanical Properties. BEYOGLU EYE JOURNAL, Cilt: 7 - Sayı: 3, 193–198. https://ajindex.com/articles/649068

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

Lazarus JH. Epidemiology of Graves orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012;26:273–9
Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid- eye clinic. Clin Endocrinol (Oxf) 1993;38:367–72
Bahn RS, Heufelder AE. Pathogenesis of Graves ophthalmopathy. N Engl J Med 1993;329:1468–75
Dolman PJ. Evaluating Graves orbitopathy. Best Pract Res Clin Endocrinol Metab 2012;26:229–48
Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg 2005;31:156–62
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves orbitopathy in a large series of patients with newly diagnosed Graves hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013;98:1443–9
Khalil HA, Van Best JA, De Keizer RJ. The permeability of the corneal epithelium of Graves ophthalmopathy as determined by fluorophotometry. Doc Ophthalmol 1989;73:249–54
Villani E, Viola F, Sala R, Salvi M, Mapelli C, Curro N, et al. Corneal involvement in Graves orbitopathy: An in vivo confocal study. Invest Ophthalmol Vis Sci 2010;51:4574–8
Unal M, Onol M, Konuk O, Aktas Z, Aksoy S. Hyperthyroidism and severity of orbital disease do not change the central corneal thickness in Graves ophthalmopathy. Eur J Ophthalmol 2008;18:125–7
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/european group on Graves orbitopathy guidelines for the management of Graves orbitopathy. Eur Thyroid J 2016;5:9–26
Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC. Graves ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015;2015:249125
Werner SC. Modification of the classification of the eye changes of Graves disease. Am J Ophthalmol 1977;83:725–7
Nardi M, Bartolomei MP, Romani A, Barca L. Intraocular pressure changes in secondary positions of gaze in normal subjects and in restrictive ocular motility disorders. Graefes Arch Clin Exp Ophthalmol 1988;226:8–10
Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy: A systematic review. Ophthalmol Ther 2020;9:21–33
Karabulut G